US Markets

Sanofi and Regeneron's Dupixent shows more encouraging results

Credit: REUTERS/BENOIT TESSIER

Healthcare companies Sanofi and Regeneron announced on Friday more encouraging results for their Dupixent product used to treat severe atopic dermatitis, often commonly known as eczema.

PARIS, April 3 (Reuters) - Healthcare companies Sanofi SASY.PA and Regeneron REGN.O announced on Friday more encouraging results for their Dupixent product used to treat severe atopic dermatitis, often commonly known as eczema.

The companies said that Dupixent Phase 3 data showed a significant improvement in severe atopic dermatitis for children aged 6 to 11 years.

Dupixent is an important driver of growth for both Sanofi and Regeneron, given the competition on Regeneron’s flagship eye drug Eylea and pressures on Sanofi’s diabetes business.

(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez)

((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

REGN

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More